|
WO2021041958A1
|
|
Chimeric proteins in autoimmunity
|
|
WO2020257762A1
|
|
Chimeric protein expressing t-cells
|
|
WO2020232365A1
|
|
Nk cell-directed chimeric proteins
|
|
WO2020176718A1
|
|
Combination therapies
|
|
US2020216505A1
|
|
Heterodimeric proteins for modulating gamma delta t cells
|
|
WO2020146393A1
|
|
Heterodimeric proteins for modulating gamma delta t cells
|
|
US2020071380A1
|
|
Combination therapies comprising sirp alpha-based chimeric proteins
|
|
US2020069733A1
|
|
FLT3L-based chimeric proteins
|
|
CA3109346A1
|
|
Combination therapies comprising sirp alpha-based chimeric proteins
|
|
AU2019328305A1
|
|
Combination therapies comprising tim-3-based chimeric proteins
|
|
AU2019333175A1
|
|
FLT3L-based chimeric proteins
|
|
WO2020047329A1
|
|
Chimeric proteins comprising extracellular domains and uses thereof
|
|
AU2019333173A1
|
|
Combination therapies
|
|
EP3810172A1
|
|
Heterodimeric proteins and uses thereof
|
|
AU2018223821A1
|
|
TIGIT- and LIGHT-based chimeric proteins
|
|
AU2018223822A1
|
|
CSF1R-based chimeric proteins
|
|
US2019367581A1
|
|
Vsig8-based chimeric proteins
|
